Facts and figures




International production facilities in eight countries.

Affiliates or offices in 75 countries.


Approximately 41,600 employees (March 2016).

Approximately 42% of employees are located in Denmark (17,888) and 58% in the rest of the world (USA: 6,384, Region China: 4,390, International Operations: 7,431, Europe: 4,483, Pacific: 1,481).
20% within research and development
32% in production and production administration
36% in international sales and marketing
12% in administration

Product areas

We have five product areas:
Diabetes care 
Growth hormone therapy
Hormone replacement therapy

According to applicable law, only health care professionals are allowed to access product information on our site. Please find the information under Health Care Professionals.

For patient and disease information, including pens and needles, please look under Patients.

Quarterly sale

27,212 million Danish kroner Q1 2016

Annual sale

107,927 million Danish kroner 
(Full year results 2015. See Financial Statement for more information)

Sales by business segment
Q1 2016

Diabetes and obesity care 21,031 million Danish kroner

Biopharmaceuticals 6,181 million Danish kroner

Sales by region
Q1 2016

USA: 13,730 million Danish kroner
Europe: 5,016 million Danish kroner
International Operations: 3,516 million Danish kroner
Region China: 2,875 million Danish kroner
Pacific:  2,075 million Danish kroner

Novo Nordisk A/S

Bagsværd, Denmark, 
CVR nr. 24 25 67 90

Novo Nordisk Annual Report 2015

Financial highlights

Download annual reports, interim reports,
investor presentations and much more in our download centre

Share information

Learn more about Novo Nordisk shares.

Novo Nordisk products

Facts about Novo Nordisk products